These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 16027402

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics.
    Simonson SG, Martin PD, Mitchell PD, Lasseter K, Gibson G, Schneck DW.
    J Clin Pharmacol; 2005 Aug; 45(8):927-34. PubMed ID: 16027403
    [Abstract] [Full Text] [Related]

  • 4. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.
    Wright DH, Herman GA, Maes A, Liu Q, Johnson-Levonas AO, Wagner JA.
    J Clin Pharmacol; 2009 Oct; 49(10):1157-67. PubMed ID: 19783710
    [Abstract] [Full Text] [Related]

  • 5. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ.
    Br J Clin Pharmacol; 2004 May; 57(5):592-9. PubMed ID: 15089812
    [Abstract] [Full Text] [Related]

  • 6. Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz JI, Liu F, Stroh M, Gipson A, Johnson-Levonas AO, Lasseter KC, Lai E, Wagner JA.
    Am J Ther; 2009 May; 16(3):215-23. PubMed ID: 19454860
    [Abstract] [Full Text] [Related]

  • 7. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
    Van Hecken A, Depré M, Verbesselt R, Wynants K, De Lepeleire I, Arnout J, Wong PH, Freeman A, Holland S, Gertz B, De Schepper PJ.
    J Clin Pharmacol; 1999 May; 39(5):495-500. PubMed ID: 10234597
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz JI, Dunbar S, Yuan J, Li S, Gipson A, Rosko K, Johnson-Levonas AO, Lasseter KC, Addy C, Stoch AS, Wagner JA.
    Adv Ther; 2008 Nov; 25(11):1175-90. PubMed ID: 18989636
    [Abstract] [Full Text] [Related]

  • 10. Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males.
    Schall R, Müller FO, Hundt HK, Duursema L, Groenewoud G, Middle MV.
    Arzneimittelforschung; 1996 Jan; 46(1):41-6. PubMed ID: 8821516
    [Abstract] [Full Text] [Related]

  • 11. Ciprofloxacin prolonged-release tablets do not affect warfarin pharmacokinetics and pharmacodynamics.
    Washington C, Hou SY, Hughes NC, Campanella C, Berner B.
    J Clin Pharmacol; 2007 Oct; 47(10):1320-6. PubMed ID: 17724088
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.
    Gu N, Kim BH, Lim KS, Kim SE, Nam WS, Yoon SH, Cho JY, Shin SG, Jang IJ, Yu KS.
    Clin Ther; 2012 Jul; 34(7):1592-600. PubMed ID: 22727611
    [Abstract] [Full Text] [Related]

  • 14. Absence of a pharmacokinetic interaction between etanercept and warfarin.
    Zhou H, Patat A, Parks V, Buckwalter M, Metzger D, Korth-Bradley J.
    J Clin Pharmacol; 2004 May; 44(5):543-50. PubMed ID: 15102876
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of effects of terbinafine on single oral dose pharmacokinetics and anticoagulant actions of warfarin in healthy volunteers.
    Guerret M, Francheteau P, Hubert M.
    Pharmacotherapy; 1997 May; 17(4):767-73. PubMed ID: 9250555
    [Abstract] [Full Text] [Related]

  • 16. Celecoxib does not significantly alter the pharmacokinetics or hypoprothrombinemic effect of warfarin in healthy subjects.
    Karim A, Tolbert D, Piergies A, Hubbard RC, Harper K, Wallemark CB, Slater M, Geis GS.
    J Clin Pharmacol; 2000 Jun; 40(6):655-63. PubMed ID: 10868317
    [Abstract] [Full Text] [Related]

  • 17. Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin.
    Kirby LC, Johnson BM, Adams LM, Eberwein DJ, Zhang K, Murray SC, Lates CD, Blum RA, Morris SR.
    J Clin Pharmacol; 2010 May; 50(5):566-75. PubMed ID: 20220045
    [Abstract] [Full Text] [Related]

  • 18. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects.
    Dieterle W, Corynen S, Mann J.
    Br J Clin Pharmacol; 2004 Oct; 58(4):433-6. PubMed ID: 15373937
    [Abstract] [Full Text] [Related]

  • 19. Lack of pharmacokinetic and pharmacodynamic interactions between a smoking cessation therapy, varenicline, and warfarin: an in vivo and in vitro study.
    Burstein AH, Clark DJ, O'Gorman M, Willavize SA, Brayman TG, Grover GS, Walsky RL, Obach RS, Faessel HM.
    J Clin Pharmacol; 2007 Nov; 47(11):1421-9. PubMed ID: 17962429
    [Abstract] [Full Text] [Related]

  • 20. Sodium pentosan polysulfate reduces urothelial responses to inflammatory stimuli via an indirect mechanism.
    Sadhukhan PC, Tchetgen MB, Rackley RR, Vasavada SP, Liou L, Bandyopadhyay SK.
    J Urol; 2002 Jul; 168(1):289-92. PubMed ID: 12050558
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.